Sophina Bauer

Dr. Sophina Bauer

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EKElena Esra Keller
Elena Esra Keller
SBSophina Bauer
Sophina Bauer
KRKarin Roider
Karin Roider
MKMichael Kleindorfer
Michael Kleindorfer
PTPeter Törzsök
Peter Törzsök
Lukas LusuardiLukas Lusuardi
Lukas Lusuardi
Bladder dysfunction is among the most drastic and quality-of-life-reducing conditions after spinal cord injury (SCI). Neuroinflammation in the lower urinary tract (LUT) after SCI could be a key driver of neurogenic bladder dysfunction and tissue fibrosis. Leukotrienes, a group of highly active lipid mediators, are potent inflammatory mediators. Here, we explored the potential of early montelukast (MLK) therapy, a cysteinyl leukotriene receptor 1 antagonist, on LUT function and structure four weeks after severe SCI in rats. Rats (strain Lewis, female, n = 50) received a permanent bladder catheter, followed by a complete T9 spinal cord transection. MLK was given daily, starting on day one post-injury. Bladder and locomotor function were regularly assessed. Bladder tissue was histologically and immunhistochemically analyzed. Post-SCI, MLK concentrations in plasma and cerebrospinal fluid were clinically relevant. MLK improved bladder functionality. MLK had no impact on smooth muscle alignment and uroepithelial integrity at this early SCI time point. This pilot study gave first insights into early, continuous oral MLK treatment with the first promising results of preserved LUT function and possible subsequent improved tissue integrity.

4 April 2025 in Biology
Verified
Journal Article
Open access
PDF file
MKMichael Kleindorfer
Michael Kleindorfer
EKElena Esra Keller
Elena Esra Keller
KRKarin Roider
Karin Roider
EBEvelyn Beyerer
Evelyn Beyerer
PHPatrick Heimel
Patrick Heimel
SBSophina Bauer
Sophina Bauer
Spinal cord injury (SCI) is a complex clinical condition with a wide range of permanent functional and neurological consequences. A prime factor limiting the patient’s quality of life (QoL) is difficulties in bladder function. Chronic animal models that help to develop novel therapeutic strategies are highly demanded, but their availability is scarce and frequently accompanied by substantial limitations. We want to provide our detailed protocols that allow full reproducibility of a novel model for investigating both the acute and chronic condition, and give transparency regarding challenges. The preclinical animal model of female rats with mid-thoracic SCI contusion and a permanently implanted urinary catheter allowed the measuring of bladder function repetitively. Over a period of six months, data were collected weekly from the same, conscious individuals. To our knowledge, this is the first study that obtained a clinically relevant urodynamic dataset seamlessly from the acute to the chronic phase in rats with SCI. The ability to generate a complete data set from one single individual, rather than requiring multiple subjects, has the potential to markedly reduce the number of experimental animals, eliminate group differences, and give more flexibility for therapeutic intervention. Future projects could also benefit from the described optimizations in animal care.

6 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SBSophina Bauer
Sophina Bauer
LGLukas Grassner
Lukas Grassner
DMDoris Maier
Doris Maier
LALudwig Aigner
Ludwig Aigner
Lukas LusuardiLukas Lusuardi
Lukas Lusuardi
EKElena Esra Keller
Elena Esra Keller
Background: A solid rationale exists for early sacral neuromodulation in the form of causal therapy that improves neurogenic lower urinary tract dysfunction after complete spinal cord injury. However, the short and early time frame for minimally invasive therapy poses a series of ethical and medical issues, which has impeded clinical realisation thus far. Objectives: We performed a cross-sectional study on patients with chronic spinal cord injury to learn about patients’ attitudes towards early treatment to prepare for large randomised controlled trials. Methods: A cohort of patients (n = 86, mixed genders) with spinal cord injury over two years was analysed. Their lower urinary tract-related quality of life was assessed using the Qualiveen-30 tool. The extent of neurogenic lower urinary tract dysfunction, patients’ awareness of it, and their attitude towards early sacral neuromodulation were explored with a specific questionnaire. Results: A total of 61.9% (n = 52) of patients declared that, in retrospect, they would have agreed to early treatment prior to the emergence of their autonomic dysfunction. Of these patients, 51.8% (n = 29) would have also consented to early sacral neuromodulation. Quality of life had no impact on their decision. More than half of the patients (n = 49, 57.0%) stated they had not grasped the momentous nature of neurogenic lower urinary tract dysfunction when being informed about it. This finding was subsequently correlated with a decreased lower urinary tract-related quality of life. Conclusion: Patients with neurogenic lower urinary tract dysfunction are likely to agree to an early therapeutic approach. Clinical implementation requires knowledge and acceptance of the procedure on the part of patients and their caregivers.

23 July 2025 in Biology
Verified
Journal Article
Open access
PDF file
SBSophina Bauer
Sophina Bauer
MKMichael Kleindorfer
Michael Kleindorfer
KRKarin Roider
Karin Roider
EBEvelyn Beyerer
Evelyn Beyerer
MBMartha Georgina Brandtner
Martha Georgina Brandtner
EKElena Esra Keller
Elena Esra Keller
Spinal cord injury (SCI) frequently leads to neurogenic lower urinary tract dysfunction, for which appropriate bladder management is essential. While clinical care relies on continuous low-pressure drainage in the acute phase, rat models commonly use twice-daily manual bladder expression—a method known to generate high intravesical pressures and retention. This study evaluated the impact of this standard practice on bladder tissue remodeling by comparing it to continuous drainage via high vesicostomy in a rat SCI model. 32 female Lewis rats underwent thoracic contusion SCI and were assigned to either manual expression or vesicostomy-based bladder management. Over eight weeks, locomotor recovery, wound healing, and bladder histology were assessed. Vesicostomy proved technically simple but required tailored wound care and calibration. Results showed significantly greater bladder wall thickness, detrusor muscle hypertrophy, urothelial thickening, collagen deposition, and mast cell infiltration in the manual expression group compared to both vesicostomy and controls. In contrast, vesicostomy animals exhibited near-control levels across most parameters. These findings highlight that commonly used bladder emptying protocols in rat SCI models may overestimate structural bladder changes and inflammatory responses. Refined drainage strategies such as vesicostomy can minimize secondary damage and improve the translational relevance of preclinical SCI research.

30 September 2026 in International Neurourology Journal
Verified
Journal Article
Open access
PDF file
MKMichael Kleindorfer
Michael Kleindorfer
KRKarin Roider
Karin Roider
KMKatia Monastyrskaya
Katia Monastyrskaya
AAAkshay Akshay
Akshay Akshay
PHPatrick Heimel
Patrick Heimel
EKElena Esra Keller
Elena Esra Keller
Purpose: Neurogenic lower urinary tract dysfunction (nLUTD) develops in nearly all patients after spinal cord injury (SCI). Evolving neuroinflammation is considered a key driver of secondary injury and is associated with worsening outcomes. However, few studies have examined treatments for nLUTD after SCI that specifically target these processes. This study investigated whether early montelukast therapy targeting proinflammatory leukotrienes improves long-term urological function and reduces pathological bladder remodeling.Methods: Female Lewis rats received a permanently implanted urinary catheter and underwent contusion SCI (Th8/Th9) or sham surgery. Daily montelukast treatment began 1 day after injury and continued throughout the 2- or 6-month follow-up period. Injury severity and regeneration were evaluated using the Basso-Beattie-Bresnahan locomotor score and microcomputed tomography of the spinal cord. Bladder function was assessed through weekly urodynamic recordings in awake animals, and bladder structure was assessed by histological measurement of wall thickness. Transcriptomic and proteomic analyses were used to characterize the molecular processes underlying bladder remodeling.Results: Spinal cord tissue damage and functional impairment were comparable across animals, regardless of treatment. Montelukast did not improve urodynamic outcomes and was associated with transiently poorer functional scores during early recovery. Bladder wall thickness increased after SCI and was greatest in the treated groups, suggesting ongoing remodeling. Transcriptomic and proteomic analyses demonstrated marked activation of immune and contractility-related pathways in treated animals at 2 months. Animals followed for the longer period showed intensified immune signaling, indicating sustained inflammatory activity.Conclusions: Early montelukast treatment did not improve functional or structural urological outcomes after contusion SCI. The unfavorable functional trends and intensified inflammatory and injury-related pathways suggested adverse effects rather than therapeutic benefit under the conditions studied. These findings may indicate the importance of injury model-specific mechanisms and of dose and timing when developing anti-inflammatory strategies for SCI-induced nLUTD.